HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 62.5%

Neg 0% Neu 0% Pos 62.5%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $50 to $65.